The pharmaceutical giants responsible for the popular obesity medications Mounjro and Ozempic are facing a lawsuit alleging that the drugs caused stomach paralysis. Personal injury firm Morgan & Morgan is representing a 44-year-old Louisiana woman with diabetes who experienced weight loss while taking the drugs, but later suffered from severe stomach paralysis that resulted in violent vomiting, tooth loss, and multiple hospital visits. The lawsuit claims that the companies, Eli Lilly and Novo Nordisk, failed to adequately warn consumers about the risk of gastroparesis. Expert attorney Paul Pennock believes there is sufficient evidence to prove the connection between the drugs and the debilitating condition. The lawsuit is just one of many that will be filed in the near future.
The patient, Jaclyn Bjorklund, initially began taking Ozempic, which is primarily prescribed for type II diabetes but is often used off-label for weight loss, in the spring of 2022. After experiencing severe stomach problems such as violent vomiting, stomach pain, and difficulty digesting food, she switched to Mounjro, another weight loss medication, in July 2023. However, the switch did not alleviate her symptoms. Other patients have also reported similar issues after stopping the use of Mounjro or other GLP-1 drugs.
Gastroparesis, or stomach paralysis, is a condition where the spontaneous movement of stomach muscles responsible for pushing food through the digestive tract is impaired. This can result in undigested food remaining in the stomach for longer periods of time. The exact causes of gastroparesis are largely unknown, but it is believed to be a complication of diabetes, which is why many patients take medications like Ozempic.
The attorney representing the patients involved in the lawsuit mentioned that approximately 400 other individuals in 45 states have sought legal assistance for damages related to the drugs. This indicates that Eli Lilly and Novo Nordisk may face a significant number of personal injury lawsuits. One patient, Emily Wright, lost 80 pounds while taking Ozempic but developed gastroparesis and vomits frequently, causing her to leave her job as a teacher. Another patient, Joanie Knight, began experiencing severe nausea and vomiting two years into taking the drug and eventually had to undergo gastric bypass surgery to improve her stomach emptying.
While the causes and long-term effects of gastroparesis and these obesity medications are still being studied, it is clear that the pharmaceutical industry is benefiting greatly from their sales. Novo Nordisk controls 94% of the branded obesity medicine market in the US and is valued at $336 billion, making it Europe’s second-most valuable company. Eli Lilly’s Mounjro is also a contender in the obesity drug market, with projected revenues of $5.4 billion by 2030 if approved by the FDA.
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
